Hypoxia News and Research

RSS

Hypoxia is a condition in which there is a decrease in the oxygen supply to a tissue. In cancer treatment, the level of hypoxia in a tumor may help predict the response of the tumor to the treatment.

Sleep apnea’s contribution to diabetic nephropathy needs attention

The effect of obstructive sleep apnea syndrome on the development of diabetic nephropathy requires investigation, say researchers.

31 Aug 2012

GeneTex to introduce new antibody against hypoxia-inducible factor 1alpha

GeneTex, Inc., a leading manufacturer of antibodies, has announced that they will be launching a new antibody against HIF1a (hypoxia-inducible factor 1alpha).

29 Aug 2012

Investigators discover biological explanation for why low levels of oxygen advance SMA symptoms

Investigators at Nationwide Children's Hospital may have discovered a biological explanation for why low levels of oxygen advance spinal muscular atrophy (SMA) symptoms and why breathing treatments help SMA patients live longer. The findings appear in Human Molecular Genetics.

22 Aug 2012

Diabetes Research Institute to receive JDRF-HCT grant for islet encapsulation study

JDRF, in collaboration with The Leona M. and Harry B. Helmsley Charitable Trust (HCT), announced today that it has finalized a grant in the area of islet cell encapsulation to Dr. Camillo Ricordi, M.D. and a team of investigators at the Diabetes Research Institute (DRI), based at the University of Miami (FL).

17 Aug 2012

Diffusion Pharmaceuticals receives new U.S. patents for trans sodium crocetinate

Diffusion Pharmaceuticals LLC, a biotechnology company focused on innovative cancer treatments, today announced that the U.S. Patent and Trademark Office has granted it patent numbers 7919527 and 8030350, entitled "Bipolar Trans Carotenoids Salts and Their Uses" and "Trans Carotenoids, Their Synthesis and Uses," respectively.

16 Aug 2012

Variations in RORA gene can lead to post-traumatic stress disorder

Investigators at Boston University School of Medicine (BUSM) and Veterans Affairs (VA) Boston Healthcare System have identified a new gene linked to post-traumatic stress disorder (PTSD).

8 Aug 2012

HSF1 increases expression of chaperones and supports cancer metastasis

Whitehead Institute researchers have found that increased expression of a specific set of genes is strongly associated with metastasis and death in patients with breast, colon, and lung cancers.

3 Aug 2012

Brain injury patterns predict outcomes in oxygen-starved infants

Patterns of brain injury in babies with neonatal hypoxic–ischemic encephalopathy predict survival and disability in late infancy, show study findings.

31 Jul 2012

‘Narrow therapeutic window’ for oxygen in brain injury

Hyperoxia, as well as hypoxia, early after hospital admission is associated with poor outcomes and mortality in patients with traumatic brain injury, report researchers in the Archives of Surgery.

27 Jul 2012

Cerulean commences dosing in CRLX101 Phase 2 study for ovarian cancer

Cerulean Pharma Inc., a leader in developing dynamically tumor-targeted nanopharmaceuticals, today announced that the first patient has been dosed in a Phase 2 study of its lead candidate, CRLX101, in platinum-resistant ovarian cancer patients.

23 Jul 2012

Chest X-ray prevents excess antibiotic use in childhood pneumonia

Use of a chest X-ray as well as traditional clinical parameters to diagnose childhood pneumonia can prevent overdiagnosis and unnecessary use of antibiotics, say researchers.

16 Jul 2012

Chest X-ray prevents excess antibiotic use in childhood pneumonia

Use of a chest X-ray as well as traditional clinical parameters to diagnose childhood pneumonia can prevent overdiagnosis and unnecessary use of antibiotics, say researchers.

10 Jul 2012

Cerulean commences dosing in CRLX101-Avastin combination study for metastatic renal cell carcinoma

Cerulean Pharma Inc., a leader in developing dynamically tumor-targeted nanopharmaceuticals, today announced that the first patient has been dosed in a Phase 1b/2a study of its lead product candidate, CRLX101, in combination with Avastin, in metastatic renal cell carcinoma (mRCC) patients. The company also announced the completion of enrollment of its randomized Phase 2 study in advanced non-small cell lung cancer.

2 Jul 2012

Enrollment complete in Cerulean CRLX101 Phase 2 study for non-small cell lung cancer

Cerulean Pharma Inc., a leader in developing dynamically tumor-targeted nanopharmaceuticals, today announced that it has completed enrollment of a randomized Phase 2 study of its lead candidate, CRLX101, in advanced non-small cell lung cancer (NSCLC). The company also announced that it has dosed the first patient in a second tumor type.

2 Jul 2012

Stanford Woods Institute awards five new EVP grants for interdisciplinary research

The Stanford Woods Institute for the Environment has awarded five new Environmental Venture Projects (EVP) grants for interdisciplinary research aimed at finding practical solutions to major environmental and sustainability challenges.

23 Jun 2012

OSA underdiagnosed among primary care diabetes patients

Obstructive sleep apnea is commonly underdiagnosed in patients with Type 2 diabetes in primary care, suggest study findings.

22 Jun 2012

New clinical data for ZEVALIN Injection for intravenous use presented at 17th EHA Congress

Spectrum Pharmaceuticals, Inc., a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology and hematology, today announced new clinical data presented in an oral presentation for ZEVALIN (ibritumomab tiuxetan) Injection for intravenous use at the 17th Congress of the European Hematology Association (EHA).

19 Jun 2012